Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diphencyprone plus intralesional glucantime for acute cutaneous leishmaniasis
IRCT20140414017271N6Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of diphencyprone and meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Rate of recovery and Time required for lesions to heal. Started Nov 2017; status: completed.
02
Drugs
diphencypronemeglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20140414017271N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140414017271N6.